Floatz logo

CLEMASTIN

Demyelination; Corpus Callosum

University of California, San FranciscoSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Demyelination; Corpus Callosum cohort.

Asset / SponsorPhaseRating
OPICINUMAB
Biogen
Phase 1CC
Humax-Cd20
Tianjin Medical University General Hospital
D
Calculus Bovis Sativus
Tongji Hospital
N/ANR

Same molecule, other indications

CLEMASTIN is also rated in:

relapsing-remitting multiple sclerosisDormant
B
Indicative ·
61 / 100
View asset →
multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
internuclear ophthalmoplegiaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →